Navigation Links
Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
Date:4/25/2011

PRINCETON, N.J., April 25, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended March 31, 2011.

Financial ResultsRevenues were $0.2 million during the quarter ended March 31, 2011 compared to $0.3 million for the quarter ended March 31, 2010 and include amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities during the three months ended March 31, 2011 was $16.8 million. Pharmasset held $208.3 million in cash and cash equivalents as of March 31, 2011.

Total operating expenses for the quarter ended March 31, 2011 were $20.8 million as compared to $15.7 million for the same period in 2010.

Pharmasset reported a net loss of $19.9 million, or $0.55 per share, for the quarter ended March 31, 2011, as compared to a net loss of $16.1 million, or $0.54 per share, for the quarter ended March 31, 2010.

Recent Operational Highlights:-- Presented SVR12 data from its ongoing Phase 2b PROTON trial with PSI-7977 in HCV genotype 2/3 patients at the European Association for the Study of the Liver (EASL) conference in April 2011

-- Presented 12 week interim analysis of the genotype 1 arms of its PROTON trial genotype 1 arms at EASL

-- Presented 14 day data from PSI-7977/PSI-938 NUCLEAR study at the EASL conference in April 2011

-- Initiated the duration finding ATOMIC trial with PSI-7977

-- Roche initiated INFORM-SVR with mericitabine (RG7128) and ritonavir boosted danoprevir (RG7227) in the first quarter of 2011

-- Decided not to file an IND for PSI-661 in order to focus resources on PSI-7977 and PSI-938.

"Pharmasset had
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 Research and Markets ... the "Latest Regulations on Pharmaceutical International Multi-Center ... offering. This is first time in ... on international multi-center clinical trials of drugs in ... to be implemented on March 1, 2015. The ...
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/5x377m/north_american ) has announced the addition of ... by Type (Ankle Replacement, Digit Replacement, Elbow ... - Forecast to 2019" report to ... market for knee replacement was valued at ...
Breaking Medicine Technology:2015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2
... Group,(Debiopharm), a global biopharmaceutical development specialist that,focuses ... announces,the filing of an application with the ... 6-month formulation of Decapeptyl(R) (triptorelin pamoate 22.5 ... for the treatment of,locally advanced or metastatic, ...
... LOS ANGELES, Sept. 24 International Medical,Corps was ... the Top 25,Members Projects, ,Saving the Lives of ... of 1,190 submissions nominated by American Express card ... by September 29 will vie for $2.5,million in ...
Cached Medicine Technology:Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients 2International Medical Corps Matched with Top 25 American Express Members Project, 'Saving the Lives of Malnourished Children' 2
(Date:5/23/2015)... CA (PRWEB) May 23, 2015 With ... small businesses, are finding it increasingly difficult to provide ... which fail to provide adequate insurance for employees stand ... businesses been such an integral part of a business’s ... affordable healthcare for businesses, Online USA Doctors has created ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Javon ... at the Sports Medicine and Rehabilitation Center, 557 N. ... program, Mondays, June 1-July 20, 5:30-6:30 pm. , The ... coach, and Laurie Finke, RN, BSN, who will offer ... education on nutrition, running mechanics and show selection and ...
(Date:5/22/2015)... San Francisco, CA (PRWEB) May 22, 2015 ... is hosting two exciting events in June. They will ... First Professional Doctorate and a two-day class on Classical ... 1:30-2:30 p.m. June 3, Dr. Steve Given, the Dean ... he will discuss the new First Professional Doctorate program. ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at ... the 2015 Congress of Future Medical Leaders in Boston, ... of “America’s highest achieving high school students.” , “I’m ... new goals and learn better study habits,” said Omar. ... which we can ask the surgeons questions.” , The ...
(Date:5/22/2015)... PITTSBURGH, Pa (PRWEB) May 22, 2015 ... Network (AHN) today announced a new partnership to ... program for the region. The initiative includes a new ... BodyStage live demonstration theater, and a new traveling ... in the fall of 2015. , Designed to ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... Just 45 minutes more shut-eye a night might make a ... While the connection between a child,s weight and the amount ... new research has found a strong correlation between the two. ... a night had a 23 percent rate of obesity, while ...
... company says drug still has benefits , , MONDAY, Nov. ... Trasylol, a clotting drug using during heart surgery to prevent ... and Drug Administration to remove the drug from the American ... patient population in which the use of Trasylol (aprotinin) outweighs ...
... In a subset of patients suffering heart attack, ... treatment window ends isn,t justified, say researchers from Duke ... last year,s widely reported Occluded Artery Trial (OAT), which ... attacks if it were used more than 3 days ...
... HONG KONG, Nov. 5 Mass Financial Corp. ... a lawsuit in the Supreme Court of,British Columbia, ... for breach of contract and contract interference. In ... Michael Smith, President of MASS said the ...
... - Operating earnings up 9 percent to $490 million, - Diluted earnings ... ... ... Supply Chain ...
... 5 Allos,Therapeutics, Inc. (Nasdaq: ALTH ) today reported ... months ended September 30, 2007, the,Company reported a net loss ... net loss of $8.1 million, or ($0.15) per share, for ... 30, 2007, the Company,reported a net loss of $28.1 million, ...
Cached Medicine News:Health News:Kids Who Skimp on Sleep Tend to Be Fatter 2Health News:Kids Who Skimp on Sleep Tend to Be Fatter 3Health News:Trasylol Pulled From Worldwide Market 2Health News:Trasylol Pulled From Worldwide Market 3Health News:Trasylol Pulled From Worldwide Market 4Health News:Delayed angioplasty -- big bucks, no bang 2Health News:Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages 2Health News:Cardinal Health Reports First Quarter Results 2Health News:Cardinal Health Reports First Quarter Results 3Health News:Cardinal Health Reports First Quarter Results 4Health News:Cardinal Health Reports First Quarter Results 5Health News:Cardinal Health Reports First Quarter Results 6Health News:Cardinal Health Reports First Quarter Results 7Health News:Cardinal Health Reports First Quarter Results 8Health News:Cardinal Health Reports First Quarter Results 9Health News:Cardinal Health Reports First Quarter Results 10Health News:Cardinal Health Reports First Quarter Results 11Health News:Cardinal Health Reports First Quarter Results 12Health News:Cardinal Health Reports First Quarter Results 13Health News:Cardinal Health Reports First Quarter Results 14Health News:Cardinal Health Reports First Quarter Results 15Health News:Cardinal Health Reports First Quarter Results 16Health News:Cardinal Health Reports First Quarter Results 17Health News:Cardinal Health Reports First Quarter Results 18Health News:Cardinal Health Reports First Quarter Results 19Health News:Cardinal Health Reports First Quarter Results 20Health News:Cardinal Health Reports First Quarter Results 21Health News:Cardinal Health Reports First Quarter Results 22Health News:Cardinal Health Reports First Quarter Results 23Health News:Cardinal Health Reports First Quarter Results 24Health News:Cardinal Health Reports First Quarter Results 25Health News:Cardinal Health Reports First Quarter Results 26Health News:Cardinal Health Reports First Quarter Results 27Health News:Cardinal Health Reports First Quarter Results 28Health News:Cardinal Health Reports First Quarter Results 29
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: